A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

Conclusions: In NCI-H292 cells that possess wild-type Keap1, Nrf2-mediated cell proliferation may be regulated by the EGFR/MAPK signaling pathway. On the other hand, in A549 cells, cell proliferation ...

You’ll have more treatment options for EGFR-positive non-small-cell lung cancer (NSCLC) now than ever before. But doctors are still testing new treatments and combinations in clinical trials.

A new research paper was published in Aging's Volume 15, Issue 13, entitled, “Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization.” ...

Citation: Classifying EGFR mutations by structure offers better way to match non-small cell lung cancer patients to treatments (2021, September 15) retrieved 8 May 2025 from https://medicalxpress ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...

The link between EGFR signaling and FBXW7 mutations is important to investigate in order to improve treatment options for colorectal cancer. Currently, many patients are treated with EGFR ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer. Amivantamab (Rybrevant, Janssen) is an EGFR-MET bispecific antibody.

Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor may recommend treating it with targeted therapies that block EGFR. Learn ...